A recent study suggests that patients who come off blockbuster slimming jabs like semaglutide or tirzepatide may regain reduced body mass far faster than those who end conventional diet and exercise plans.
Published data in a major medical journal shows that while obese people frequently drop substantial amounts of their body weight while using the jabs, the weight returns at an estimated rate of nearly a kilo each month after stopping.
"Users buying these treatments must be informed of the risk of fast rebound weight gain when the treatment is stopped," stated researcher Dr. Susan Jebb.
That rate of recovery suggests a return to starting mass within about one and a half years.
Analyzing Approaches
The research, which examined 37 of trials involving thousands of participants, compared the outcomes of these new drugs with conventional dieting.
Scientists note that people who lose weight through diet and exercise typically see a less rapid weight regain—around 0.1 kg a month—after stopping.
Explaining the Fast Regain
Experts suggest the mode of action of the drugs explains the heightened regain.
The injections mimic a natural hormone called glucagon-like peptide-1, which controls hunger.
"Sustained high doses of the hormone levels far above than the body's typical production could lead to the system to generate a reduced amount of its own natural GLP-1, and may also reduce sensitivity to its effects," noted Dr. Adam Collins, a nutrition expert.
"Stopping of this medication means hunger is unsuppressed, making excessive eating far more likely."
A Chronic Condition?
Health authorities recommend the injections for individuals with weight-linked medical conditions, alongside recommended lifestyle changes.
A number of clinicians contend that, given the significant potential of weight regain, the therapy is often life-long.
This view is supported by pharmaceutical companies, who note that the findings "emphasize the long-term nature of excess weight," comparing it to managing diseases like diabetes.
User Experiences
Users who have discontinued the medication explain a powerful resurgence of hunger.
"It was like a trigger activating and you're instantly extremely hungry," said one woman.
This difficulty is exacerbated if users have not developed permanent dietary or behavioural changes during therapy.
Growing Use
Figures show that a significant number of people in the UK have tried weight-loss jabs in the past year, with interest continuing to grow.
- Use is greater among women than males.
- The middle-aged demographic shows the highest level of interest.
- A large proportion access the medications through private healthcare rather than public health services.
Ultimately, experts emphasize that while these medications are effective agents for weight loss, they are not a standalone solution and long-term success hinges on integrated behavioural support.
